Evaluación de la quimioterapia amenorrea inducida (CIA) en receptores hormonales positivos mujeres premenopáusicas con cáncer de mama

Chemotherapy induced amenorrhea (CIA) is associated with improved disease free survival (DFS) in women with ER/PR-positive breast cancer and no association was observed in those with ER/PR-negative tumors. To assess the incidence of chemotherapy induced amenorrhea (CIA) with the addition of taxanes to anthracycline regimen in premenopausal patients diagnosed as hormone receptor positive breast cancer. A retrospective study was carried out at Amala cancer hospital & research centre, Kerala. Patients were placed in to two subgroups depending on the type of chemotherapy that had been administered: anthracyclines regimens either with or without taxanes. Out of 50 ER+/PR+ patients considered, 36 were on anthracycline regimen alone (Group 1)and14 were on anthracycline + taxane regimen (Group 2) and.100% of group 2 and (75%) of group 1 experienced CIA (P=0.0470, RR=1.333).The permanency of CIA was also high in group 2 than in group 1. (64.2% Vs 48.1%) (P=0.5100, RR=1.335). A slight increase in CIA was prevalent in women >40yrs (89.6% Vs 71.4%) (P=0.1404, RR=1.255) The permanency of CIA was also high in patients who were >40 yrs old (69.2% Vs 26.6%) (P=0.0115, RR=2.596) Our study concluded the higher incidence of CIA in Anthracycline + taxane group than Anthracycline alone that can increase disease free survival in ER+/PR+ breast cancer patients.

KEY WORDS:

chemotherapy induced amenorrhea, ER+/PR+ breast cancer, anthracyclines, taxanes.